The aim of the trial is to determine the timing for orotracheal intubation using the studied combination of products (Ultiva + Diprivan). MedDRA version: 12.0 Level: LLT Classification code 10042609 Term: Surgery
Conditions
Interventions
Trade Name: Ultiva
Product Name: ULTIVA
Product Code: Remifentanil
Pharmaceutical Form: Concentrate for solution for injection
Trade Name: Diprivan
Product Name: Diprivan
Pharmaceutical Form: Solutio
Sponsors
Erasme hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ASA I or II patients (as classified by the American Society of Anesthesiologist) undergoing an elective gynecological or gastroenterological surgery. Patients must be older than 18 and youger than 60 years of age. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: ASA score higher than II. Patients under 18 and over 60 years of age. History of intravenous drug abuse. Anticipated difficult airway. Body mass index higher than 30.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine the time needed for orotracheal intubation in a rapid sequence induction using Ultiva and Diprivan as sole agents.;Secondary Objective: Evaluate the hemodynamic response to orotracheal intubation in this setting.;Primary end point(s): Time to orotracheal intubation. | — |
Countries
Belgium
Outcome results
None listed